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Abstract: Large bacterial protein toxins autotranslocate
functional effector domains to the eukaryotic cell cytosol,
resulting in alterations to cellular functions that ultimately
benefit the infecting pathogen. Among these toxins, the
clostridial glucosylating toxins (CGTs) produced by Gram-
positive bacteria and the multifunctional-autoprocessing
RTX (MARTX) toxins of Gram-negative bacteria have
distinct mechanisms for effector translocation, but a
shared mechanism of post-translocation autoprocessing
that releases these functional domains from the large
holotoxins. These toxins carry an embedded cysteine
protease domain (CPD) that is activated for autoproces-
sing by binding inositol hexakisphosphate (InsP6), a
molecule found exclusively in eukaryotic cells. Thus,
InsP6-induced autoprocessing represents a unique mech-
anism for toxin effector delivery specifically within the
target cell. This review summarizes recent studies of the
structural and molecular events for activation of autopro-
cessing for both CGT and MARTX toxins, demonstrating
both similar and potentially distinct aspects of autopro-
cessing among the toxins that utilize this method of
activation and effector delivery.
Introduction
Pathogenic bacteria frequently export protein toxins that target
eukaryotic intracellular proteins to alter host cell function to the
benefit of the infectious pathogen. Different exported toxins
employ distinct strategies for translocation of their cytopathic
effectors from the bacterium into the host cell. These strategies
include direct injection, such as occurs using Type III, Type IV
[1], and likely also Type VI secretion [2]. By contrast, some toxins
are secreted or released from the bacteria and then bind to host
cell surface receptors via a binding (B) component. The B
component itself or a separate translocation component then
transfers the catalytic subunit or domain across the plasma or
endosomal membrane into the cytosol. In some toxins, the B
component is a protein subunit assembled with the effector (A)
subunit within the bacteria before export (such as cholera toxin
[3]), while for other toxins, the B and A subunits are exported
separately and then assembled at the surface of the target cell (such
as anthrax toxin [4]). Still other toxins are expressed as a single
polypeptide that is nicked to separate the A and B domains by
endogenous bacterial proteases (such as botulinum toxin [5]) or by
host cell proteases during translocation (such as diphtheria toxin
[6]). All of these processes succeed in delivering the smaller active
effector domains or subunits into the host cell, where they can then
access their intracellular protein targets.
Yet, questions have remained as to how single polypeptide
toxins that range in size from 250 to 600 kDa deliver their effector
domains to the eukaryotic cytosol. A shared strategy for activation
of autocatalytic processing upon binding of the eukaryotic signal
molecule inositol hexakisphosphate (InsP6) has recently been
characterized for these toxins. This process represents a novel
strategy for toxin activation and subsequent delivery of effectors to
target cells.
Overview of Clostridial Glucosylating Toxins
Clostridial glucosylating toxins (CGTs), also known as large
clostridial cytotoxins, are structurally and functionally related
toxins produced by different Clostridium sp. that range in size from
250 to 308 kDa and have sequence identity from 26% to 76%
[7,8]. Clostridium difficile Toxin A (TcdA) and Toxin B (TcdB) are
the major virulence factors of clinically important antibiotic-
associated diarrheal infections and pseudomembranous colitis [9].
Recent studies revealed that, while some C. difficile strains produce
both toxins, only TcdB is essential for virulence [10]. Other
significant members of the CGT family are Lethal Toxin from C.
sordellii (TcsL) and the a-toxin from C. novyi (Tcna). These
clostridia are more rare causes of disease, but have been associated
with particularly severe invasive infections, including gas gangrene
and toxic shock following abortions or gynecological procedures
[11–14].
The CGTs are organized in a multidomain structure [15],
including a biologically active effector domain, a middle
translocation domain, and a C-terminal receptor-binding domain
[8] (Figure 1A). To enter eukaryotic target cells, the secreted
CGTs bind to extracellular receptors and follow the ‘‘short trip
model’’ of exotoxin uptake [16]. After receptor-mediated endocy-
tosis, a vesicular H
+-ATPase leads to acidification of the early
endosomes, inducing a conformational change and an increase in
hydrophobicity [17]. A small hydrophobic region of the protein is
proposed to form a pore through which the N-terminus-localized
glucosyltransferase (GT) domain is translocated into the cytosol
[18–20]. Using UDP-glucose (UDP-N-acetylglucosamine for
Tcna) as a co-substrate, the GT monoglucosylates Rho family
GTPases. The covalent modification occurs at a specific threonine
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Thr35 in Rac), thereby preventing activation of the small GTPases
by exchange of GTP for GDP. Ultimately, the accumulation of
inactive GTPases results in reorganization of the cytoskeleton and
other morphological changes [21].
Overview of Multifunctional-Autoprocessing RTX
Toxins
Multifunctional-autoprocessing RTX (MARTX) toxins are
larger toxins that range in size from 350 to 600 kDa [22]. The
MARTX toxin of Vibrio cholerae (MARTXVc) has been linked to
virulence, in which the toxin functions during early infection to
promote colonization, possibly by inactivating cellular innate
immunity [23–25]. The MARTX toxins from both human [26–
29] and aquatic animal [30] infectious Vibrio vulnificus strains
(MARTXVv) and the fish pathogen Vibrio anguillarum (MARTXVa)
[31] have likewise been associated with virulence. In addition,
putative MARTX toxins have been identified in at least 13 other
sequenced Gram-negative bacteria, including Proteus, Aeromonas,
Yersinia, and Photorhabdus spp. [22,32–36], suggesting that
additional pathogens require these toxins as virulence factors.
Similar to CGTs, the MARTX toxins are modular in structure,
but are typified by the presence of extensive repeats at both the N-
and C-termini [22,37]. These repeats are postulated to form the
translocation structure for transfer of centrally located effector
domains to the cytosol [22] (Figure 1B). For MARTXVc,
cytopathic effects occur in the presence of inhibitors of endocytosis
[38–40], suggesting that endocytosis is not required for MARTX
toxin entry, as it is for the CGTs.
Among the various MARTX toxins, a total of ten potential
effectors have been identified, although each independent toxin
has an assortment of only one to five [22]. The best-characterized
MARTX effector is the actin crosslinking domain (ACD),
which introduces a Glu270-Lys50 isopeptide linkage between
actin monomers by a mechanism similar to that for glutamine
synthetases [41,42]. Another MARTX effector inactivates
RhoGTPases by an unknown mechanism [43], although a recent
bioinformatics study suggested this domain is a thiol protease
[44]. The remaining eight potential effectors are domains of
unknown function, even though two share sequence homology
with Photorhabdus luminescens and Pasteurella multocida toxins and
one is conserved with the alpha/beta hydrolase family of
proteins [22].
Figure 1. Schematic diagrams representing CPD-dependent autoprocessing sites within CGTs and MARTX toxins. Diagrams are
shown for (A) CGTs represented by TcdA and TcdB or (B) MARTX toxins represented by MARTXVc. In (A), the CGT holotoxins contain C-terminal
repeats required for receptor interactions and a hydrophobic region (HR) postulated to function in translocation of the GT across the membrane of
the endosome. Upon autoprocessing, the catalytically active glucosyltransferase effector (GT) is delivered to cells where it targets RhoGTPases. In (B),
the MARTX holotoxin contains both N- and C-terminal repeats that likely function in translocation. Upon autoprocessing, MARTXVc delivers three
effectors that have distinct cellular targets as indicated. For both diagrams, the CPD catalytic Cys and His are marked, as are processing site Leu
residues (see Table 1) found in unstructured segments between effectors (indicated by arrows). For CGTs, sequence numbering above the diagram
represents TcdA while numbering below the diagram represents TcdB. For MARTXVc, sequence numbering is based on the original annotation of the
rtxA gene by Lin et al. [37] and may be different than that found in cited references.
doi:10.1371/journal.ppat.1000942.g001
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Autoprocessing by a Conserved Cysteine
Protease Domain
Early studies of the CGTs postulated that they would undergo
enzymatic processing after exposure to low pH [17,45]. Subse-
quent in vivo studies demonstrated that only the 60-kDa GT
effector of TcdB is delivered to the cytosol, while a larger C-
terminal fragment remains in the membrane fraction [20]. This
processing of TcdB also occurred in vitro after residue Leu543,
with a strict dependence upon addition of eukaryotic cell lysate
[46] (Figure 1A). These studies of TcdB were initially interpreted
as indicating processing by a host cell–encoded protease, similar to
the mechanism for maturation of diphtheria toxin and other
bacteria toxins [6]. However, protein-free extracts also stimulated
TcdB processing, indicating autocataytic cleavage [47].
Similarly, early studies of MARTXVc postulated that the ACD
would need to be released by proteolysis to access the entire actin
pool [40]. In fact, it has been demonstrated that MARTXVc is
autoprocessed at four positions located before and after its three
effector domains, resulting in the release of these domains from the
holotoxin [48,49] (Figure 1B).
The autoprotease domain responsible for MARTXVc processing
was recognized first as a 25-kDa domain within MARTXVc that
affected cell viability when ectopically expressed in eukaryotic cells
[50]. This cytotoxicity was disrupted by mutation of a single Cys or
Hisresidue,andanalysisofprotein expressionpatternsrevealedthat
the mutant proteins were the predicted size, while the wild-type
protein was cleaved of its N-terminus. Studies with recombinant
protein confirmed autoprocessing after Leu3428 and, similar to
TcdB, processing was strictly dependent upon addition of protein-
free cell cytosol extracts [50]. Mutation of the critical Cys in the full-
length toxin significantly reduced the ability of the toxin to induce
actin crosslinking, confirming autoproteolysis due to this cysteine
protease domain (CPD) enhanced toxin function [50].
After its discovery within MARTXVc, the CPD was found to be
conserved within all MARTX toxins and also in all CGTs, with
common alignment of the processing sites and the catalytic Cys
and His residues [50,51]. Furthermore, for TcdB, mutation of the
analogous Cys and His residues reduced cytotoxicity of the full-
length toxin, and disrupted processing of recombinant CPD
protein as well [51,52]. Thus, it was recognized that both the
CGTs and MARTX toxins share a common mechanism for
autocatalytic processing inducible by protein-free eukaryotic cell
cytosol and that autoprocessing is essential for optimal cytotoxicity.
InsP6: The Inducer of Autoprocessing
To identify the molecule in cell cytosol required to induce CPD
for autoprocessing, cell extracts that stimulated processing of TcdB
were fractionated and analysis of active fractions by mass
spectrometry supplied spectra with similarities to inositol phos-
phates [47]. Incubation of TcdB with several inositol phosphates
indicated that InsP6 induced the most efficient autoprocessing
activity [47]. Similar studies indicated that InsP6 is likewise the
most effective stimulator of autoprocessing of the MARTXVc CPD
[53].
As a signal molecule for the eukaryotic intracellular environment,
InsP6 (also known as phytic acid) is an excellent selection for
bacterial toxins, since the molecule is ubiquitous in eukaryotes but
absent in bacteria. Furthermore, InsP6 is the most abundant of the
inositol phosphates, is maintained within cells at relatively constant
levels of 10–60 mM, and is generally freely soluble in the cytoplasm
[54]. Within mammalian cells, InsP6 may function as a high
concentration storage molecule for phosphate as it does in plant
seeds or as a highly charged buffer for cation- or protein-dependent
processes. More recent studies have linked InsP6 to numerous
cellular processes, including vesicle recycling, mRNA transport out
of the nucleus, and as a co-factor for a DNA-dependent protein
kinase [54]. Regardless of its normal function, InsP6 is a molecule
constantly present in high concentrations in the eukaryotic cytosol,
assuring that induction of CGT and MARTX CPDs occurs only
after completion of translocation of effector domains to the cytosol,
regardless of whether translocation requires endocytosis or transfer
directly across the plasma membrane.
InsP6 Binding to the CPDs
While both CGT and MARTX CPDs are induced for
autoprocessing by InsP6, there are differences in these proteins
revealed by crystallography and InsP6 binding studies that suggest
slightly different mechanisms of activation. Mutational studies
[53,55–57] and analysis of four independent crystal structures
[48,49,56,57] revealed that binding of InsP6 to the CPD involves
contact of the six negatively charged phosphate groups within a
positively charged pocket of the CPD (Figure 2). The most
significant binding contacts of MARTXVc with InsP6 involve
Lys3482, Lys3611, and Lys3623. Other Lys, Arg, and positively
charged residues that form the binding pocket are not essential for
binding, but do contribute to the high affinity of the MARTXVc
CPD for InsP6 [53,56]. In TcdB, Lys600 (analogous to Lys3481 of
MARTXVc) is likewise essential for binding of InsP6 [55], while
other conserved Lys and Arg residues also contact InsP6 [55,57].
Interestingly, overlay of the structures of the CPD from
MARTXVc and TcdA CPDs revealed that the orientation of
InsP6 in the binding pocket is not conserved [57] (Figure 2), which
is a surprise since amino acid sequence alignments show strong
conservation of the Lys and Arg residues that form the binding
pocket [55,57]. However, this difference in the structure of the
binding pocket may in part account for variances revealed in
studies of InsP6 binding and CPD activation for the different
CPDs.
Intramolecular processing of purified MARTXVc CPD was
found to be optimal in the range of 0.001–1 mM InsP6 [53,56],
and binding of InsP6 occurred with affinities ranging from 0.2 to
1.3 mM InsP6 [48,53,56]. The ability of MARTXVc CPD to
complete autoprocessing in vitro at concentrations below the
dissociation constant reflects the recycling of InsP6 released from
processed CPD back to predominantly unprocessed protein [53],
since processed MARTXVc CPD has a 500-fold reduced affinity
for InsP6 [48].
By contrast, activation of purified TcdB CPD autoprocessing
requires 2 mM InsP6 [51], a concentration near the determined Kd
of 2.3 mM [55]. Furthermore, recombinant TcdB CPD that
mimics protein processed after Leu543 binds InsP6 with a similar
affinity as full-length TcdB and unprocessed recombinant CPD
[55], suggesting that TcdB CPD, unlike MARTXVc CPD, does
not have an altered affinity for InsP6 after processing.
Although the dissociation constant has not as yet been
determined for TcdA, processing studies indicate that its ability
to bind InsP6 may be less efficient than TcdB. Whereas full-length
TcdB is cleaved to completion at InsP6 concentrations of 2–10 mM
[47,51], full-length TcdA does not autoprocess at 10 mM InsP6
and concentrations up to 10 mM have been used for experimen-
tation [47,51]. However, recombinant TcdA CPD does autopro-
cess at concentrations as low as 5 mM [57], suggesting that the
affinity of TcdA CPD for InsP6 could be near to that of TcdB, but
not accurately reflected in holotoxin cleavage assays.
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binding pocket and binding kinetics, the high affinity of the
unprocessed CPDs for InsP6 indicates that autoprocessing of
MARTXVc, TcdB, and TcdA would all proceed efficiently at
InsP6 concentrations of 10–60 mM that are found in the eukaryotic
cell cytosol [54]. Thus, all of the studied CGT and MARTX
toxins would be autoprocessed and effectively deliver their effector
domains within the in vivo environment.
Structural Arrangement of the CPD Catalytic Site
The CPD catalytic dyad is composed of one His and one Cys
residue separated by ,6A ˚ in both MARTXVc and TcdA
structures [48,56,57] (Figure 3A–3D). The distance between the
catalytic residues indicates that the Cys is not activated by
protonation from His, but rather suggests that the Cys is substrate-
activated by close alignment of the scissile bond, while the His
functions solely to protonate the leaving group [48,57].
In addition, Asp and Glu residues play an essential function in
proteolysis. Mutation of TcdB Asp567 or TcdA Asp589 disrupted
autoprocessing [51,57] and eliminated cytopathic effects when
added to HeLa cells [55]. By contrast, mutation of the analogous
Asp3469 in the MARTXVc CPD did not affect autoprocessing [53].
Analysis of the structural models indicates that this conserved Asp
residue functions inboth proteinstoproperlyorient thecatalyticHis
residue [48,57] (Figure 3A–3D). However, in the MARTXVc CPD
structure, this function is shared with residue Glu3467, such that
only a double Asp/Glu mutant is defective for function [53].
The closest known cysteine proteases that share this structural
arrangement of the catalytic site are caspase-1 and gingipain R
[58,59]. Similar to these other proteases [60,61], the CPDs are
resistant to cysteine protease inhibitor E64 [50], but sensitive to N-
ethylmaleimide, iodoacetamide, or chloromethyl ketones
[48,50,51]. Thus, the CGT and MARTX toxin CPDs are
grouped together with caspase-1 and gingipain R in the CD clan
of cysteine proteases, but form a new family, the C80 family
(http://merops.sanger.ac.uk, [62]). The CPD proteases have also
been incorporated into a larger CPDadh family of putative
bacterial and eukaryotic peptidase that are proposed to share a
similar fold in the catalytic site [63].
Structure-Based Modeling of InsP6-Induced
Activation of the CPDs
As the binding site for InsP6 occurs on the opposite side of the
protein from the catalytic site (Figure 3E–3H), it was recognized
that there must be a mechanism to transduce the binding signal
across the entire protein structure [56]. Translocation of effector
domains of both CGTs and MARTX toxins is predicted to involve
transit through a pore for entry into the cytosol, and thus the CPD
is likely partially unfolded when it is first presented to the InsP6-
rich environment of the cytosol [15,22]. Consistent with this
model, apo-CPD in the absence of InsP6 for both MARTXVc and
TcdA is highly sensitive to proteolysis [48,57]. Nuclear magnetic
resonance (NMR) studies of the TcdA CPD indicated that the
apo-protein is folded, but undergoes a significant conformational
reorganization upon InsP6 binding [57]. This finding is consistent
with an observed high negative enthalpy and entropy and a 14uC
thermal stability shift upon binding of InsP6 to MARTXVc CPD,
suggesting that this protein undergoes a major structural
rearrangement that also stabilizes the protein structure [48].
Upon binding InsP6, the structure of the MARTXVc CPD
adopts the stable conformation amenable to X-ray crystallography
(Figure 3E–3G). The CPD is composed of a seven-stranded b-
Figure 2. Side chain residues from CPD that contact InsP6 in the structural models derived from crystal structures of MARTXVc and
TcdA CPD. All key residues that contact InsP6 in the CPD of (A) MARTXVc and (B) TcdA are shown labeled with a single letter code, with the three Lys
residues determined to be most critical for InsP6 binding shown in bold text. Interestingly, despite strong conservation of the critical Lys residues in
the primary amino acid sequence, contacts with InsP6 and the orientation of InsP6 differ in the two structures. Diagram is colored to represent
residues originating from the N-terminal strand (yellow), the core structure (green), and b-strands G1-G5 (blue), a structure also known as b8-b12 or
the b-flap. Structural models were based on PDB (A) 3FZY [48] and (B) 3HO6 [57], and figures were prepared with MacPyMol software (DeLano
Scientific).
doi:10.1371/journal.ppat.1000942.g002
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sheet [56]. An additional five b-strands at the C-terminus form a
subdomain, known as the b-flap, that is loosely attached to the
core of the protease [56]. By contrast, the TcdA CPD is larger and
consists of a nine-stranded b-sheet flanked by five a-helices
(Figure 3G) [57]. In both proteins, the N-terminus is an
unstructured strand wrapped around the outside of the protein
and attached to the core structure by embedding of large
hydrophobic residues [48,57]. At the extreme N-terminus of the
CPD, the P1 Leu residue found immediately before the scissile
bond is buried in a hydrophobic pocket (Figure 3E) [48].
Mutagenesis studies and structural analysis [48,49] have demon-
strated that Leu is the only residue that can be accommodated at
this position. On either side of the Leu, any residue can occur but
there is a preference for small residues, creating a consensus
sequence of small-Leu-small ([48,49] and Table 1). The G1 b-
strand (also known as b8) forms part of the hydrophobic pocket
[56], and conserved Leu and Val residues on this strand make
direct contact with the P1 Leu before the scissile bond [48]. This
G1 strand is antiparallel to the G2 b-strand (also known as b9), a
strand that contributes positively charged amino acids that make
contact with InsP6 [56]. The current model for activation of the
MARTXVc CPD proposes that binding of InsP6 alters the
structure of this antiparallel b-hairpin, resulting in stabilization
of the N-terminus within the hydrophobic pocket [48] and possibly
reorientation of the catalytic Cys [56]. The net effect is to orient
the scissile bond between the catalytic Cys and His residues,
resulting in substrate-activated autoprocessing [48] (Figure 4). A
similar mechanism has been proposed for the activation of TcdA
CPD [57].
Multisite Processing of MARTXVc
The CGT toxins require only a single processing event to
release their GT effector domain (Figure 1A), and this may
account for why activation apparently requires a structural change
between two apparently stable conformations at approximately
5 mM InsP6 [57]. By contrast, MARTX toxins must undergo
processing at multiple sites to release each of the effectors
independently [48,49] (Figure 1B). A simplistic model of multisite
processing would predict that activation of the CPD by binding of
InsP6 results in transition to a constitutive ‘‘on’’ conformation after
which it processes all accessible sites immediately [56]. Yet,
biochemical studies described above indicated that after processing
of its own N-terminus, MARTXVc CPD converts to an inactive
conformation with a 500-fold reduced affinity for InsP6
(Kd=100 mM) [48] (Figure 4). Since this concentration is above
the upper limit of the in vivo concentration of InsP6 [54], only a
small fraction of processed CPD would bind InsP6 in vivo, limiting
the likelihood of multisite processing. However, it was found that
reactivation of MARTXVc CPD for high affinity binding of InsP6
occurs after insertion of a new substrate into the hydrophobic
pocket, indicating cooperativity of substrate and InsP6 binding
[48]. Both binding studies [48] and crystallography [49]
(Figure 3G) have shown that chloromethyl ketone and epoxide
inhibitors bound to Leu can substitute for a new substrate to
Figure 3. Crystal structures of MARTXVc and TcdA CPDs. Crystal structures of the (A–D) CPD catalytic sites with distances between residues
designated in angstroms and (E–G) the CPD proteins are shown at various stages of processing. (A, E) Pre-processing and (B, F) post-processing
structures of MARTXVc CPD bound to InsP6 (PDB 3FZY [48] and PDB 3EEB [56], respectively). (C, G) Post-processing structures of TcdA CPD bound to
InsP6 (PDB 3HO6 [57]). (D, H) Post-processing structure of MARTXVc bound to z-Leu-Leu-azaLeu-epoxide inhibitor JCP598 as a surrogate substrate
representing the structure of CPD after reactivation (PDB 3GCD [49]). Structures are identically oriented at a conserved Trp (purple) in the G1/G2 b-
hairpin that is critical to InsP6 induction of autoprocessing [56]. The catalytic Cys and His residues are shown in pink with InsP6 present at the backside
of each structure in red. The P1 Leu (turquoise) is found only in the unprocessed structure (A) with the scissile bond oriented between the catalytic
residues. Figures were prepared with MacPyMol software (DeLano Scientific).
doi:10.1371/journal.ppat.1000942.g003
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reactivation, the protein is able to process any other available
processing sites [48,49], although there is a preference for
processing within the same molecule of MARTXVc, indicating
there may be a physical association of the CPD with the effector
domains [48].
Figure 4. Proposed model for cooperative activation and reactivation of MARTXVc CPD by InsP6. I. Apo-CPD without InsP6 is an unstable
protein susceptible to thermal denaturation at physiological temperature. The core structure (green) is folded but the b-flap (blue) is susceptible to
proteolysis, indicating it may be only partially structured. II. Upon binding InsP6, the structure rearranges such that the N-terminus (yellow) becomes
locked within the active site between the catalytic Cys (C) and His (H) in a rigid alignment amenable to substrate-activated autoprocessing. III. After
autoprocessing, the MARTXVc CPD enters a transitional state that has distinct biochemical properties, including a 500-fold reduced affinity for InsP6.
IV. After first binding a new substrate (grey) and then a new molecule of InsP6, the enzyme–substrate complex structure of the MARTXVc CPD is
restored for additional processing events. Figure is based on multisite processing model for MARTXVc proposed by Prochazkova et al. [48]. Current
evidence from NMR studies supports the idea that stage I and II also occur for TcdA [57]. However, binding studies with TcdB suggest CGTs likely do
not undergo stage III deactivation or stage IV reactivation [55].
doi:10.1371/journal.ppat.1000942.g004
Table 1. InsP6-induced autoprocessing CGTs and MARTX toxins.
Toxin Group Bacterial Toxin (Abbreviation) Number of Effectors
a Cellular Targets
a Processing Sites
b Reference
CGT C. difficile Toxin A (TcdA) 1 RhoGTPases GGSL542QSED (p) [47,51]
C. difficile 8864 Toxin B (TcdB8864) 1 RhoGTPases EGAL543QGED (m) [46]
C. difficile 10463 Toxin B (TcdB) 1 RhoGTPases EGSL543QGED (m) [46]
C. novyi Alpha toxin (Tcna) 1 RhoGTPases GRTL548QNYE (p) [46,47]
C. sordellii Lethal toxin (TcsL) 1 RhoGTPases EGAL543QGED (p) [46]
MARTX V. cholerae MARTXVc 3 Actin, RhoGTPases, ?? LESL1658QSAV (m) [48]
LHAL2434QGET (m) [48,49]
LDAL3085QSGN (m) [48,49]
KEAL3428QADG (m) [50]
QQGL3402QDTT (a) [49]
NDHL3419QAVV (a) [48]
V. vulnificus MARTXVv 5 RhoGTPases, ?? KGSL4089QSGA (m) [49]
P. luminescens MARTXplu1341 1 ?? LQAL2538QSGK (p) [49]
P. luminescens MARTXplu1344 2 ?? SGAL2962QMSQ (p) [49]
P. luminescens MARTXplu3217 1 ?? LDWL2408QSGK (m) [49]
VEAL2405QDWL (a) [49]
P. luminescens MARTXplu3324 1 ?? LEGL2418QSGT (p) [49]
aBased on analysis of effector domains as reviewed in [15,22].
bProcessing site is indicated by inverted arrow. m, processing site as mapped experimentally by N-terminal sequencing or mass spectrometry; p, processing site
predicted by homology to mapped processing site from closely related toxin; a, alternative processing site identified by mass spectrometry. Numbering of MARTXVc
processing sites is based on amino acid sequence as originally annotated in [37] and may be different than that found in cited references. For other MARTX toxins, not
all processing sites are known and only those previously reported in the literature are listed.
doi:10.1371/journal.ppat.1000942.t001
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Intervention
The discovery of InsP6-induced autoproteolysis as a critical
stage for activation and effector delivery for large bacterial toxins
raises the potential for anti-toxin small molecules to be developed
as therapeutics. TcdB is the most significant virulence factor of C.
difficile [9,10], and it is conceivable that specific TcdB anti-toxin
drugs could be combined with antibiotic and anti-toxin antibody
therapies for treatment of recurrent antibiotic-associated diarrhea
[64]. In addition, the contribution of MARTXVv to V. vulnificus
septicemic infection is significant [26–29], suggesting that anti-
MARTXVv CPD therapeutics may be of interest, particularly
since there are currently no anti-toxin treatments for these rapidly
progressing fatal infections. By contrast, clinical intervention
against any domain of MARTXVc during cholera disease is
impractical since animal studies suggest that MARTXVc functions
only during the earliest stage of infection, prior to the onset of
symptoms [24,25]. Indeed, classical V. cholerae strains responsible
for severe cholera during the fifth and sixth pandemics have a
natural deletion in the rtxA gene that encodes MARTXVc,
demonstrating that it is dispensable for late stage infection [37].
For research purposes, potent small molecule inhibitors of the
MARTXVc CPD activity have been identified. These include
peptidyl (acyloxy)methyl ketone epoxide [49] and chloromethyl
ketone [48] inhibitors in which the amino acid leucine is linked to
the functional group independently or as part of a tripeptide. Both
classes of inhibitor are cysteine reactive and become covalently
linked to the catalytic cysteine (Figure 3D). However, analysis of
the pre-processed form of MARTXVc CPD revealed the N-
terminus is bound within the active site prior to InsP6 binding,
which occludes access of the catalytic Cys to protease inhibitors.
Thus, inactivation of the CPD with Cys reactive inhibitors
requires long incubation times of up to 30 minutes [48]. Yet, upon
initial intramolecular processing immediately upstream of the
CPD, the catalytic Cys is exposed, facilitating rapid inhibition of
subsequent processing events that release effectors [48,49].
Consistent with these in vitro findings, exogenous addition of the
membrane permeant z-Leu-Leu-azaLeu-epoxide inhibitor
JCP598 to culture cells reduced actin crosslinking in vivo [49],
suggesting inhibitors could be useful at a critical point after CPD
translocation.
Similar inhibition studies using the more clinically relevant
TcdB remain to be performed. Since the CGTs are only
processed one time (Figure 1A), there is a concern that cysteine
reactive inhibitors would be ineffective if the N-terminus bound
in the active site blocks access to the catalytic Cys. A structure of
the enzyme-substrate complex of TcdA or TcdB CPD is not yet
available and inhibition by N-ethylmaleimide has been performed
only with 30 minutes of incubation [51]. Thus, it is unknown if
the accessibility of the Cys will be blocked similar to MARTXVc
CPD. As described above, binding of InsP6 to the recombinant
TcdB CPD protein with the P1 leucine removed has been
measured and shown to be similar to that with the Leu attached
[55]. These results thereby suggest the association of the N-
terminus with the TcdB catalytic site and relevant exposure of the
catalytic site to inhibitors may differ from MARTXVc CPD.
Hence, the potential for inhibition of InsP6-induced autoproces-
sing by CPDs as a therapeutic intervention against TcdB merits
further exploration. If access to the cysteine is indeed found to be
blocked, the CPD could still be a suitable target for therapeutics,
but with molecules that mimic InsP6 itself to promote processing
outside of cells, potentially disrupting the entire translocation/
activation process.
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